Axsome Therapeutics

AXSM

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$1.1m

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$244.77

+44.8% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+44.8%Q2 ’26

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

1Q2 ’25

0Q3 ’25

0Q4 ’25

1Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Axsome Therapeutics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Axsome Therapeutics

Polen Capital Management	0.0%$1.1m	$1.1m	Added +111%	2 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works

From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.

Sort by

Insider purchases and sales of Axsome Therapeutics
		Bought or sold				Filing
3 Sep 2026	Jacobson Mark L.Chief Operating Officer	▼ Sold	10,000	$208.65	$2.1m	Form 4
6 Aug 2026	Tabuteau HerriotChief Executive Officer	▼ Sold	4,660	$213.95	$997k	Form 4
5 Aug 2026	Tabuteau HerriotChief Executive Officer	▼ Sold	45,004	$212.01	$9.5m	Form 4

About the company

Sector: Health care · Pharmaceutical Preparations
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 52m at 3 Aug 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

2014

2015

2016

2017

2018

2019

2020

2021

$50.0m2022

$271m2023

$386m2024

$638m2025

Axsome Therapeutics revenue and net income by year
Year	Revenue	Net income
2025	$638m	−$183m
2024	$386m	−$287m
2023	$271m	−$239m
2022	$50.0m	−$187m
2021	–	−$130m
2020	–	−$103m
2019	–	−$68.3m
2018	–	−$31.0m
2017	–	−$28.9m
2016	–	−$27.2m
2015	–	−$12.2m
2014	–	−$6.0m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.